On March 4, 2021, Kizoo Technology Capital ("KIZOO") of Germany announced that it had provided seed funding for Elastrin Therapeutics ("Elastrin").

Elastrin is a biotechnology startup based in South Carolina and leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.

Robert Hull of Gowling WLG advised one of the co-founders of Elastrin with respect to the negotiation of this funding.